Alger Health Sciences Fund (Prospectus Summary) | Alger Health Sciences Fund

Alger Health Sciences Fund

INVESTMENT OBJECTIVE

Alger Health Sciences Fund seeks long-term capital appreciation.

FUND FEES AND EXPENSES

This table describes the fees and expenses that you may pay if you buy and hold
shares of the Fund. You may qualify for sales charge discounts if you and your
family invest, or agree to invest in the future, at least $25,000 in Class A
Shares of the Alger Family of Funds, including the Fund. More information about
these and other discounts is available from your financial professional and in
"Purchasing and Redeeming Fund Shares" beginning on page A-2 of the Fund's
Prospectus and the sections "Right of Accumulation (Class A Shares)" and "Letter
of Intent (Class A Shares)" on page 20 of the Fund's Statement of Additional
Information.

Shareholder Fees (fees paid directly from your investment)

Shareholder Fees Alger Health Sciences Fund	Class A	Class B	Class C
Maximum sales charge (load) imposed on purchases as a % of offering price	5.25%	none	none
Maximum deferred sales charge (load) as a % of purchase price or redemption proceeds, whichever is lower	none	5.00%	1.00%
Redemption Fee (as a % of amount redeemed or exchanged within 30 days)	2.00%	2.00%	2.00%

Annual Fund Operating Expenses (expenses that you pay each year as a percentage of the value of your investment)

Annual Fund Operating Expenses Alger Health Sciences Fund	Class A	Class B	Class C
Management Fees	0.81%	0.81%	0.81%
Distribution and/or Service (12b-1) Fees	0.25%	1.00%	1.00%
Other Expenses	0.29%	0.35%	0.31%
Total Annual Fund Operating Expenses	1.35%	2.16%	2.12%

EXAMPLE

The following examples are intended to help you compare the cost of investing in
the Fund with the cost of investing in other mutual funds. The examples assume
that you invest $10,000.00 in the Fund for the time periods indicated, that your
investment has a 5% return each year and that the Fund's operating expenses
remain the same.

Although your actual costs may be higher or lower, based on these assumptions you would pay the following expenses if you redeemed your shares at the end of each period:

Expense Example Alger Health Sciences Fund (USD $)	Expense Example, With Redemption, 1 Year	Expense Example, With Redemption, 3 Years	Expense Example, With Redemption, 5 Years	Expense Example, With Redemption, 10 Years
Class A	655	930	1,226	2,064
Class B	719	976	1,359	2,287
Class C	315	664	1,139	2,452

You would pay the following expenses if you did not redeem your shares:

Expense Example, No Redemption Alger Health Sciences Fund (USD $)	Expense Example, No Redemption, 1 Year	Expense Example, No Redemption, 3 Years	Expense Example, No Redemption, 5 Years	Expense Example, No Redemption, 10 Years
Class A	655	930	1,226	2,064
Class B	219	676	1,159	2,287
Class C	215	664	1,139	2,452

PORTFOLIO TURNOVER

The Fund pays transaction costs, such as commissions, when it buys and sells
securities (or "turns over" its portfolio). A higher portfolio turnover rate
may indicate higher transaction costs and may result in higher taxes when Fund
shares are held in a taxable account. These costs, which are not reflected in
annual fund operating expenses or in the examples, affect the Fund's performance.
During the most recent fiscal year, the Fund's portfolio turnover rate was 63.17%
of the average value of its portfolio.

PRINCIPAL INVESTMENT STRATEGY

Fred Alger Management, Inc. believes companies undergoing Positive Dynamic
Change offer the best investment opportunities. Positive Dynamic Change refers
to companies realizing High Unit Volume Growth or companies undergoing Positive
Lifecycle Change. High Unit Volume Growth companies are traditional growth
companies experiencing, for example, significantly growing demand or market
dominance. Positive Lifecycle Change companies are, for example, companies
benefitting from regulatory change, a new product introduction or management
change.

Under normal circumstances, the Fund invests at least 80% of its net assets,
plus any borrowings for investment purposes, in equity securities of companies
of any market capitalization that are engaged in the health sciences sector. A
company will be considered to be engaged in the health sciences sector if it
derives at least 50% of its earnings or revenues from, or devotes at least 50%
of its assets to, activities in any area of the health sciences sector,
including health care services, pharmaceuticals, medical equipment and supplies
and applied research and development. Such companies include, but are not
limited to:

• hospitals, clinical test laboratories, convalescent and mental health care
facilities, home care providers, and companies that supply services to any of
the foregoing;

• companies involved in pharmaceuticals, biotechnology, biochemistry and
diagnostics; and

• producers and manufacturers of medical, dental and optical supplies and
equipment.

The Fund can leverage, that is, borrow money to buy additional securities. By
borrowing money, the Fund has the potential to increase its returns if the
increase in the value of the securities purchased exceeds the cost of borrowing,
including interest paid on the money borrowed.

The Fund can also invest in derivative instruments. The Fund currently expects
that its primary uses of derivatives will involve: (1) purchasing put and call
options and selling (writing) covered put and call options, on securities and
securities indexes, to increase gain, to hedge against the risk of unfavorable
price movements in the underlying securities, or to provide diversification of
risk, and (2) entering into forward currency contracts to hedge the Fund's
foreign currency exposure when it holds, or proposes to hold, non-U.S. dollar
denominated securities.

PRINCIPAL RISKS

As with any fund that invests in stocks, your investment will fluctuate in value,
and the loss of your investment is a risk of investing. The Fund's price per
share will fluctuate due to changes in the market prices of its investments.
Also, the Fund's investments may not grow as fast as the rate of inflation and
stocks tend to be more volatile than some other investments you could make, such
as bonds.

Prices of growth stocks tend to be higher in relation to their companies'earnings
and may be more sensitive to market, political and economic developments than
other stocks, making their prices more volatile. An investment in the Fund may
be better suited to investors who seek long-term capital growth and can tolerate
fluctuations in their investment's value.

A small investment in derivatives could have a potentially large impact on the
Fund's performance. When purchasing options, the Fund bears the risk that if the
market value of the underlying security does not move to a level that would make
exercise of the option profitable, the option will expire unexercised. When a
call option written by the Fund is exercised, the Fund will not participate in
any increase in the underlying security's value above the exercise price. When a
put option written by the Fund is exercised, the Fund will be required to
purchase the underlying security at a price in excess of its market value. Use
of options on securities indexes is subject to the risk that trading in the
options may be interrupted if trading in certain securities included in the
index is interrupted, the risk that price movements in the Fund's portfolio
securities may not correlate precisely with movements in the level of an index,
and the risk that Fred Alger Management, Inc. may not predict correctly
movements in the direction of a particular market or of the stock market
generally. Because certain options may require settlement in cash, the Fund may
be forced to liquidate portfolio securities to meet settlement obligations.
Forward currency contracts are subject to currency exchange rate risks, the risk
of non-performance by the contract counterparty, and the risk that Fred Alger
Management, Inc. may not predict accurately future foreign exchange rates.

The following risks also apply:

• investing in companies of all capitalizations involves the risk that smaller
issuers in which the Fund invests may have limited product lines or financial
resources, or lack management depth.

• it may be difficult or impossible to liquidate a security position at a time
and price acceptable to the Fund because of the potentially less frequent
trading of stocks of smaller market capitalization.

• the cost of borrowing money to leverage may exceed the returns for the
securities purchased or the securities purchased may actually go down in value;
thus, the Fund's net asset value could decrease more quickly than if it had not
borrowed.

• since the Fund concentrates its investments in the health sciences sector, the
value of the Fund's shares may be more volatile than mutual funds that do not
similarly concentrate their investments. Furthermore, because many of the
industries in the health sciences sector are subject to substantial government
regulation, changes in applicable regulations could adversely affect companies
in those industries. In addition, the comparative rapidity of product
development and technological advancement in many areas of the sector may be
reflected in greater volatility of the stocks of companies operating in those
areas.

PERFORMANCE

The following bar chart and the table beneath it provide some indication of the
risks of investing in the Fund by showing changes in the Fund's performance from
year to year and by showing how the Fund's average annual returns for the
indicated periods compare with those of an appropriate benchmark of market
performance. Performance in the bar chart does not reflect the effect of the
sales charge imposed on purchases of Class A Shares of the Fund. If the bar
chart reflected the applicable sales charges, returns would be less than those
shown. Remember that the Fund's past performance (before and after taxes) is not
necessarily an indication of how it will perform in the future. Updated
performance information is available on the Fund's website www.alger.com.

ANNUAL TOTAL RETURN FOR CLASS A SHARES as of December 31 (%)

Best Quarter:
Q2 2003  16.75%

Worst Quarter
Q4 2008  -16.20

AVERAGE ANNUAL TOTAL RETURN AS OF DECEMBER 31, 2011

Average Annual Total Returns Alger Health Sciences Fund	Average Annual Returns, Label	Average Annual Returns, 1 Year	Average Annual Returns, 5 Years	Average Annual Returns, Since Inception	Average Annual Returns, Inception Date
Class A	Class A Return Before Taxes	4.81%	3.34%	9.15%	May 01, 2002
Class A After Taxes on Distributions	Class A Return After Taxes on Distributions	4.81%	2.86%	8.49%	May 01, 2002
Class A After Taxes on Distributions and Sales	Class A Return After Taxes on Distributions and Sale of Fund Shares	3.13%	2.61%	7.76%	May 01, 2002
Class B	Class B Return Before Taxes	4.73%	3.27%	9.06%	May 01, 2002
Class C	Class C Return Before Taxes	8.78%	3.65%	8.93%	May 01, 2002
S&P 500 Index	S&P 500 Index (reflects no deduction for fees, expenses or taxes)	2.11%	(0.25%)	3.57%	May 01, 2002

In the foregoing table, after-tax returns are calculated using the historical
highest individual federal marginal income tax rates and do not reflect the
impact of state and local taxes. Actual after-tax returns depend on an
investor's tax situation and may differ from those shown. The after-tax returns
shown may not be relevant to investors who hold their Fund shares through
tax-deferred arrangements, such as 401(k) plans or individual retirement
accounts. After-tax returns for Class B and C Shares, which are not shown, will
vary from those shown for Class A Shares. A "return after taxes on distributions
and sale of fund shares" may sometimes be higher than the other two return
figures; this happens where there is a capital loss on redemptions, giving rise
to a tax benefit to the shareholder.